Department of Health and Human Services, through National Institutes of Health, awarded Immport Therapeutics Inc of Irvine, CA $592,254 under the SBIR program (Phase II), with work starting 2025-08-25 and running to 2027-07-31. It is one of 4 SBIR and STTR awards Immport Therapeutics Inc received in the last two years, $1,792,254 in all. Each figure links to the federal record.
The award
| Recipient | Immport Therapeutics Inc (Irvine, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $592,254 |
| Period of performance starts | 2025-08-25 |
| Period of performance ends | 2027-07-31 |
| Award number | R43AI195168 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Irvine, Orange County, CA |
| Recipient registry id (UEI) | ZJAMPJY7M149 |
Want the whole picture on Immport Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immport Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immport Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
34 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
A sensitive and specific serology test for evaluating potency of whole cell pertussis vaccines - whooping cough (pertussis) is a highly contagious respiratory disease caused by the gram-negative bacterium, bordetella per
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-06 | Continuation | 000 | $292,254 |
| 2025-08-25 | New | 000 | $300,000 |
A sensitive and specific serology test for evaluating potency of whole cell pertussis vaccines - whooping cough (pertussis) is a highly contagious respiratory disease caused by the gram-negative bacterium, bordetella pertussis. In most of the world, infants receive a whole cell pertussis (wp) vaccine in conjunction with diphtheria and tetanus (dtwp). With tens of millions of doses of dtwp administered globally each year, evaluation of vaccine potency is a critical step for manufacturers toward vaccine release. First established in 1947 and still in use today, the kendrick assay is the method of evaluating wp potency. As a labor intensive and highly variable mouse intracerebral challenge protocol, the kendrick assay constitutes a bottleneck in dtwp vaccine release. There have been efforts to replace the kendrick assay with a pertussis serology potency test (pspt) based on a whole pertussis bacteria elisa, but the pspt suffers from issues of sensitivity and variability. Antigen discovery, inc. And dr. Nicholas mantis and colleagues at the division of infectious diseases, wadsworth center, new york state department of health are collaborating in an effort to develop a pspt based on discovery of new b. Pertussis antigens that may serve as indicators of wp vaccine potency. In the proposed study, a b. Pertussis proteome microarray will be developed to identify serological markers ass ...
From the federal award record.
Other SBIR and STTR awards to Immport Therapeutics Inc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-09 | Department of Health and Human Services | SBIR Phase I | $300,000 | Identification of protective human monoclonal antibodies for passive immunization against (record) |
| 2026-08-26 | Department of Health and Human Services | SBIR Phase II | $300,000 | Discovery of group a streptococcus antigens for development of broadly effective vaccine c (record) |
| 2025-08-12 | Department of Health and Human Services | SBIR Phase I | $600,000 | Optimizing immunogenicity of novel cryptosporidium vaccine candidates - cryptosporidiosis (record) |
Every other federal award to Immport Therapeutics Inc on record
The federal register lists 37 or more other awards to the same registry id (UEI ZJAMPJY7M149), $14,701,036 in all, from 3 agencies.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2024-09-10 | National Institutes of Health | $300,000 | SBIR 133 - antigen (75N93024C00044) |
| 2024-07-19 | National Institutes of Health | $350,250 | Humoral immunity to enteric viruses among infants and mothers in bangladesh - humoral immunity to enteric viru (R21AI185887) |
| 2023-08-17 | Centers for Disease Control and Prevention | $179,000 | Mpox microarray (75D30123P17414) |
| 2022-06-01 | National Institute of Food and Agriculture | $642,250 | **awards issued prior to january 20, 2025, were funded under previous administrations and may not reflect the (20226701537127) |
| 2021-09-30 | Centers for Disease Control and Prevention | $243,000 | Identification of serodiagnostic epitopes for SARS-COV-2, endemic hcov?s and influenza virus (R43IP001168) |
| 2021-07-20 | Agricultural Research Service | $12,000 | Antigen discovery microarray study (12305B21P0167) |
| 2021-05-12 | National Institutes of Health | $596,034 | Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine cand (R43AI157561) |
| 2020-09-30 | Centers for Disease Control and Prevention | $200,000 | Identification of brucella canis and b. Abortus RB51 seroreactive proteins and serology assay development (75D30120P09520) |
| 2020-09-01 | Centers for Disease Control and Prevention | $72,000 | COVID-19 vitro transcription/translation (75D30120P09676) |
| 2020-04-01 | National Institutes of Health | $599,999 | Scanning the cryptosporidium proteome for vaccine antigens (R43AI145607) |
| 2020-01-01 | National Institutes of Health | $600,000 | Discovery of treponema pallidum antigens for development of a sensitive and specific diagnostic test for syphi (R43AI149804) |
| 2019-08-19 | Centers for Disease Control and Prevention | $110,458 | Adi leptospirosis work (75D30119P06349) |
| 2018-09-10 | Centers for Disease Control and Prevention | $150,000 | SBIR Phase I igf::OT::igf (75D30118P02540) |
| 2018-08-22 | Centers for Disease Control and Prevention | $50,000 | Purchase of custom microarrays (75D30118P03032) |
| 2018-08-16 | National Institutes of Health | $225,707 | Pan-hiv incidence assay development (R43AI136196) |
| 2018-03-22 | National Institutes of Health | $224,852 | Protective biomarkers for the development of novel serotype-independent protein-based vaccine candidates again (R43AI138827) |
| 2018-01-16 | National Institutes of Health | $595,243 | Discovery of yellow fever virus-specific epitopes for development of an accurate serodiagnostic assay (R43AI136197) |
| 2017-03-30 | Centers for Disease Control and Prevention | $15,000 | Testing of scientific samples (HHSD2002017M93455P) |
| 2017-02-06 | National Institutes of Health | $224,958 | Specific detection of antibodies to emerging and established arboviruses including zika virus (R43AI132078) |
| 2016-08-01 | National Institutes of Health | $224,911 | A novel immuno-proteomic approach to a genital herpes vaccine (R43AI124911) |
| 2015-08-20 | National Institutes of Health | $225,000 | Point of care detection of oral pathogens (R43DE025440) |
| 2014-09-30 | Department of State | $24,000 | *"other function" - lab testing service igf::OT::igf (SPE50014M2261) |
| 2014-09-16 | National Institutes of Health | $225,000 | Development of a pan-hiv proteomic chip (R43DE025165) |
| 2014-07-17 | Centers for Disease Control and Prevention | $39,900 | Lab supplies (HHSD2002014M59788P) |
| 2014-06-05 | Animal and Plant Health Inspection Service | $4,510 | Brucella proteome microarray (AG6197P140271) |
| 2014-02-24 | National Institutes of Health | $5,680 | , for other functions, protein anaylsis of samples. (HHSN272201400326P) |
| 2014-02-10 | National Institutes of Health | $4,000 | Antigen discovery, inc. (ambis #1665217) (HHSN272201400300P) |
| 2013-04-25 | Centers for Disease Control and Prevention | $22,400 | Orthopox full proteome microarray A800 arrays (HHSD2002013M55067P) |
| 2012-09-06 | National Institutes of Health | $15,000 | Ambis# 1606350P. Falciparum custom protein microarrays (HHSN272201200808P) |
| 2012-08-01 | National Institutes of Health | $600,000 | Integrated microfluidic platform for point-of-care serodiagnostics (R43AI102288) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Immport Therapeutics IncLook up Immport Therapeutics Inc first. Finding the company and seeing how much is on record uses no credits.
Look up Immport Therapeutics IncWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.